Compare SPHR & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPHR | FOLD |
|---|---|---|
| Founded | 2020 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | N/A | 2007 |
| Metric | SPHR | FOLD |
|---|---|---|
| Price | $93.21 | $14.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $73.00 | $27.56 |
| AVG Volume (30 Days) | 706.6K | ★ 19.8M |
| Earning Date | 11-04-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,075,530,000.00 | $598,704,000.00 |
| Revenue This Year | $13.76 | $21.49 |
| Revenue Next Year | $9.67 | $18.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.28 |
| 52 Week Low | $23.89 | $5.51 |
| 52 Week High | $97.20 | $14.36 |
| Indicator | SPHR | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 90.78 |
| Support Level | $90.41 | $14.21 |
| Resistance Level | $95.06 | $14.27 |
| Average True Range (ATR) | 3.10 | 0.11 |
| MACD | -0.51 | 0.07 |
| Stochastic Oscillator | 62.11 | 97.45 |
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.